Klow 80mg pen
£75.00
Klow pen Key facts The Klow Stack is a four-peptide research formulation supplied as a single vial that combines GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg) and TB-500 (10mg) — 80mg total. GHK-Cu, a copper-peptide complex, is studied for copper-dependent signalling; KPV, an α-MSH (11-13) tripeptide, is investigated for melanocortin-linked and inflammatory signalling; BPC-157 serves as a probe for peptide-mediated signalling mechanisms; and TB-500, a thymosin beta-4 fragment, is studied for actin and cytoskeletal dynamics. Presenting four peptides with distinct mechanisms in one vial lets researchers investigate combined activity across multiple signalling pathways simultaneously, supporting exploration of convergent and parallel signalling across copper-dependent, melanocortin-linked and cytoskeletal routes, and comparison of individual versus combined activity under standardised conditions. It is supplied as a vial with a Certificate of Analysis and stored refrigerated at 2–8°C. The Klow Stack is supplied strictly for in-vitro laboratory research use only — not for human or veterinary use, and carrying no therapeutic claims. KLOW is a four-peptide research formulation, sold variously as the KLOW blend, KLOW 80mg or — as we list it — the Klow Stack. The name is an industry convention rather than a brand: wherever you see it, it refers to the same four compounds in one vial, GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg) and TB-500 (10mg), 80mg total. Presenting four peptides with distinct mechanisms in one vial lets researchers investigate combined activity across multiple signalling pathways simultaneously, under standardised conditions. What is in KLOW The name is most readily understood as KPV added to GLOW — the three-compound Glow Stack with the α-MSH fragment incl
6 in stock